GammaGard Liquid, Immune Globulin Intravenous (Human)


Allergy and Immunology, Pediatrics


Baxter BioScience and FDA notified healthcare professionals of a market withdrawal being conducted as a precautionary measure due to an increased number of adverse event reports of allergic reactions associated with two lots of the product.


GammaGard Liquid is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity.


Customers are asked to contact Baxter BioScience for Urgent Market Withdrawal instructions. See the Market Withdrawal Notice for information on affected lots.

Read the complete MedWatch 2010 Safety summary, including a link to the Market Withdrawal Notice